echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > Boehringer sells Bedford Laboratories to Hikma Pharmaceuticals for US$300 million

    Boehringer sells Bedford Laboratories to Hikma Pharmaceuticals for US$300 million

    • Last Update: 2014-05-30
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Source: dingxiangyuan sold Bedford laboratories, its troubled sterile injection subsidiary, to hikma pharmaceutical for us $300 million on May 30, 2014 Bedford in the United States is part of the Ben venue laboratories division in Bingham, a subsidiary that has received public attention in recent years for its efforts to correct quality problems Boehringer ingelham has said that he intends to close the Ben venue facility by the end of 2013, because the cost of bringing it back to normal is very high, and more than 1000 people are unemployed after the closure Less than 300 are still in factories For now, the deal with hikma seems to save the plant, which is described as one of the world's largest producers of sterile injections The UK based company said it would be able to retain some of Bedford's staff, but it did not disclose the number In addition to the production facilities, hikma will also acquire ownership of Bedford's 84 injection generics and many contracts to manufacture drugs for other companies, saying that "it plans to reintroduce planned acquisitions to address critical supply shortages in the US market." After the FDA forced it to suspend production temporarily, Boehringer Ingelheim had invested $300 million to continue production by the end of 2012, and the company said it would cost another $700 million to get the company fully on track in the next five years Hikma doesn't seem to be afraid of this challenge, perhaps because it will get a rapid upgrade, be able to deliver about 30% of Bedford drugs to its plants in the United States, Portugal and Germany, and may launch these products to these countries between 2015 and 2017 A statement from the company said Bedford may play a more professional role in the future, focusing on its freeze-drying powder capacity and facilities for the production of cytotoxic drug products, but its ultimate fate is uncertain Ohio officials said they were cautiously optimistic that the Ben venue plant would be rescued from the acquisition Original address: http://www.pmlive.com/pharma'news/boehringer'sales'injectables'business'to'hikma'for $300m'5739
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.